Jensen Investment Management Inc. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 15.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,786,087 shares of the company’s stock after selling 509,740 shares during the period. Johnson & Johnson makes up 3.4% of Jensen Investment Management Inc.’s holdings, making the stock its 14th largest position. Jensen Investment Management Inc. owned approximately 0.11% of Johnson & Johnson worth $427,469,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Moneta Group Investment Advisors LLC grew its holdings in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth about $4,609,399,000. Morgan Stanley grew its holdings in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares in the last quarter. Finally, Savant Capital LLC boosted its position in Johnson & Johnson by 8,568.8% during the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after purchasing an additional 3,588,251 shares in the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,163 shares of company stock worth $7,928,856. Corporate insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Report on Johnson & Johnson
Johnson & Johnson Price Performance
JNJ stock opened at $172.92 on Wednesday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The stock’s 50 day moving average price is $165.50 and its 200 day moving average price is $161.20. The firm has a market cap of $449.41 billion, a P/E ratio of 35.00, a PEG ratio of 2.92 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.59 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- The Significance of Brokerage Rankings in Stock Selection
- On Holding Slips Into A More Comfortable Price PointÂ
- Most Volatile Stocks, What Investors Need to Know
- 3 Growing Cannabis Stocks Ready To Bloom
- How Can Investors Benefit From After-Hours Trading
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
